Clinical Trials Browser

Phase 1 × Hereditary Sensory and Autonomic Neuropathies × 30 days × Clear all

NCT07064122 2026-03-02

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Phase 1 Recruiting

Hereditary Sensory and Autonomic Neuropathies